Mankind Pharma Limited (MANKIND) — Board Meeting

1 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approved divestment of Broadway Hospitality and incorporation of Netherlands subsidiary for R&D investments.

🔄 What Changed
Divestment of non-core asset and creation of Dutch SPV for R&D activities.

🔮 What's Next
Sale completion within 90 days; Netherlands subsidiary incorporation pending regulatory approvals.

💡 Investor Takeaway
Divestment generates ₹49 crores cash while establishing a dedicated vehicle for future R&D investments.

Mankind Pharma's board approved divesting its 100% stake in Broadway Hospitality Services Private Limited for ₹49 crores and incorporated a Netherlands subsidiary to hold R&D investments. The sale targets completion within 90 days to AKRK Projects LLP, a non-promoter buyer. The new Dutch entity will receive up to €5 million in phased investments for niche therapy development.

2 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approved divestment of Broadway and incorporation of Netherlands subsidiary for R&D.

🔄 What Changed
Divestment of non-core asset and creation of Dutch SPV for R&D investments.

🔮 What's Next
Completion of Broadway sale within 90 days; Dutch subsidiary incorporation pending regulatory approvals.

💡 Investor Takeaway
Divestment may improve focus on core pharma business while R&D expansion could drive future growth.

Mankind Pharma announced board approval to divest its 100% stake in Broadway Hospitality Services and incorporate a Netherlands subsidiary for R&D investments. The Broadway sale to AKRK Projects LLP includes ₹49 crores consideration with completion expected within 90 days. The new Dutch entity will hold up to €5 million in equity for niche therapy development.

3 Board Meeting 🟡 Notable Neutral 📄 PDF

📢 Key Event
Board approved divestment of Broadway Hospitality Services and incorporation of Netherlands subsidiary for R&D investments.

🔄 What Changed
Divestment of non-core asset and creation of Netherlands subsidiary for R&D activities.

🔮 What's Next
Sale completion within 90 days; Netherlands subsidiary incorporation pending regulatory approvals.

💡 Investor Takeaway
Divestment may improve focus on core pharma operations but could dilute non-core revenue streams.

Mankind Pharma's board approved divesting its 100% stake in Broadway Hospitality Services Private Limited for ₹49 crores and establishing a Netherlands subsidiary to hold R&D investments, with the sale expected to close within 90 days.

📊 Stock Analysis — MANKIND ✨ Ask AI About This